Who is sponsoring NCT04219267?

NCT04219267 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT04219267?

Interventions in NCT04219267: character strengths-based intervention, early memories.

What condition does NCT04219267 study?

NCT04219267 studies Breast Cancer.

Is NCT04219267 still recruiting?

NCT04219267 is currently completed. Last updated 27 January 2021.

Last reviewed 2021-01-27 · How we verify

NCT04219267

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Character Strengths-based Intervention Among Breast Cancer Patients

Completed NA Last updated 27 January 2021

What this trial tests

NA trial testing character strengths-based intervention in Breast Cancer in 122 participants. Completed in 20 December 2020.

Timeline

4 May 2020

Primary endpoint
30 November 2020

20 December 2020

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	122
Start date	4 May 2020
Primary completion	30 November 2020
Estimated completion	20 December 2020
Sites	2 locations across China

Drugs / interventions tested

character strengths-based intervention
early memories

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The research design is a randomized control trial to evaluate the effectiveness of character strengths-based intervention in enhancing self-esteem, quality of life and alleviating depression in breast cancer patients. The type of intervention is psychological intervention. Participants in the intervention group will receive character strengths-based intervention. Participants in the control group will receive placebo control care.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Development of an evidence‑based, theory‑driven, and culturally appropriate character strengths-based intervention for breast cancer patients, following the Medical Research Council Framework.
Yan T, Chan CWH, Chow KM, Xiao J, et al · · 2022 · cited 5× · PMID 36525147 · DOI 10.1007/s00520-022-07538-w
Experiences and perception of character strengths among patients with breast cancer in China: a qualitative study.
Yan T, Chan CWH, Chow KM, Li M. · · 2022 · cited 4× · PMID 36307158 · DOI 10.1136/bmjopen-2022-061994

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04219267 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 27 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04219267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing